Epinephrine Auto Injectors Market
Epinephrine Auto-Injectors Market Forecasts to 2030 - Global Analysis By Product (Single-dose Auto-Injectors and Multi-dose Auto-Injectors), Dosage, Age Group, Brand, Application, End User and By Geography
According to Stratistics MRC, the Global Epinephrine Auto-Injectors Market is accounted for $2.33 billion in 2024 and is expected to reach $3.37 billion by 2030 growing at a CAGR of 6.3% during the forecast period. Epinephrine auto-injectors are medical devices designed for emergency self-administration of epinephrine, a life-saving medication used to treat severe allergic reactions (anaphylaxis). These compact, portable devices contain a pre-measured dose of epinephrine and feature a spring-loaded mechanism for rapid injection into the thigh muscle. They provide quick relief by constricting blood vessels, relaxing airway muscles, and reversing symptoms like swelling, low blood pressure, and breathing difficulties. Commonly used by individuals with severe allergies, they are essential for immediate response during life-threatening allergic emergencies.
According to World Health Organization reports, over 16 billion injections were administered annually worldwide in 2021, stimulated by the increasing number of injections administered boosting the auto injector market.
Market Dynamics:
Driver:
Rising prevalence of anaphylaxis
The number of cases of severe allergic responses rises; the necessity for quick treatment alternatives becomes increasingly important. Epinephrine auto-injectors provide a fast and convenient way to administer life-saving medication in emergencies. Growing awareness about anaphylaxis and its risks has led to a heightened demand for these devices. The market is further fuelled by advancements in auto-injector technology, offering user-friendly designs. With an expanding at-risk population, epinephrine auto-injectors are becoming an essential tool for managing anaphylaxis, ensuring a sustained market growth.
Restraint:
Product recalls and malfunctions
Product recalls and malfunctions like failed delivery of auto-injectors to accurate doses during emergencies, it poses severe health risks, deterring users from relying on them. Recalls disrupt the supply chain and create shortages, leaving patients without access to critical medical devices. Additionally, recalls often lead to increased regulatory scrutiny, delaying new product approvals and market expansions. The financial burden of recalls and associated lawsuits also impacts manufacturers, limiting their ability to invest in innovation.
Opportunity:
Expansion of indications
The new medical conditions, such as food allergies and insect stings, are identified as requiring immediate epinephrine treatment, the demand for auto-injectors rises. Additionally, healthcare organizations are increasingly recognizing the importance of carrying auto-injectors for emergency use, further increasing their adoption. This broader usage across various demographics enhances market reach. Advancements in formulation and device design also contribute to greater patient compliance and ease of use. Ultimately, the expanded indications improve awareness and access, driving higher market penetration and sales.
Threat:
Legal and ethical concerns
High prices of auto-injectors, often attributed to patent protections, raise ethical questions about accessibility, especially for low-income patients. Regulatory hurdles and lawsuits over pricing and monopolistic practices create a challenging legal environment for manufacturers. Ethical concerns also arise from a lack of generic alternatives, limiting affordability and market competition. Liability issues related to device malfunctions or incorrect usage further deter innovation and investment. These factors collectively hinder the market’s growth and broader adoption of life-saving auto-injectors.
Covid-19 Impact
The COVID-19 pandemic significantly impacted the epinephrine auto-injectors market. Disruptions in supply chains, reduced patient visits to healthcare facilities, and delayed elective treatments initially hindered market growth. However, the heightened focus on respiratory health and self-care led to increased demand for at-home treatment solutions, benefiting the market. Telemedicine and online pharmacies emerged as key distribution channels during lockdowns. Manufacturers adapted by ramping up production and ensuring accessibility. The market demonstrated resilience, with gradual recovery aligning with improved healthcare access and the normalization of supply chains post-pandemic.
The single-dose auto-injectors segment is expected to be the largest during the forecast period
The single-dose auto-injectors segment is estimated to have a lucrative growth, by offering convenience and ease of use for individuals facing severe allergic reactions. These devices provide quick, self-administered doses, ensuring timely epinephrine delivery in emergencies. They are designed for portability, making them suitable for on-the-go use, which increases their adoption rates. Furthermore, regulatory approvals and innovations in design have enhanced the accessibility and effectiveness of single-dose auto-injectors. As a result, this segment continues to contribute significantly to the growth of the overall market.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period, due to immediate access to life-saving treatment for anaphylactic emergencies. Hospitals often serve as the primary setting for patients experiencing severe allergic reactions, where rapid administration of epinephrine is critical. With increasing allergic reactions globally, hospitals are stocking more auto-injectors to meet emergency needs. Additionally, healthcare professionals' awareness and training in using epinephrine auto-injectors drive their adoption in hospitals.
Region with largest share:
Asia Pacific is expected to hold the largest market share during the forecast period due to rising awareness of anaphylaxis and its management, coupled with increasing prevalence of food allergies and other severe allergic reactions. Countries like China, India, and Japan are seeing growing demand due to improved healthcare access and government initiatives promoting allergy management. Technological advancements in auto-injector design, such as compact and user-friendly devices, are also boosting adoption. Additionally, rising investments by pharmaceutical companies and collaborations for local manufacturing are enhancing availability and affordability across the region.
Region with highest CAGR:
North America is expected to have the highest CAGR over the forecast period, owing to increasing prevalence of anaphylactic reactions and allergies. Rising awareness about emergency treatment for allergic reactions and the need for quick medical intervention are boosting demand. The U.S. dominates the market due to high adoption rates, healthcare infrastructure, and the availability of various brands like EpiPen and Auvi-Q. Regulatory support, along with expanding insurance coverage, is further propelling the market.
Key players in the market
Some of the key players profiled in the Epinephrine Auto-Injectors Market include Viatris Inc., Amneal Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Kaléo, Inc., Pfizer, Inc., Sanofi S.A., Adamis Pharmaceuticals Corporation, Novartis International AG, Bausch Health Companies Inc., ALK-Abelló A/S, Hikma Pharmaceuticals PLC, Antares Pharma, Inc., Meridian Medical Technologies, Inc., Becton, Dickinson and Company and Ypsomed Holding AG.
Key Developments:
In October 2024, Viatris entered into an exclusive licensing agreement to acquire rights to sotagliflozin in all markets outside the U.S. and Europe. The partnership aims to enhance the commercial reach of sotagliflozin, which is relevant for patients with diabetes and heart failure.
In February 2024, Viatris announced a significant global research and development collaboration with Idorsia Ltd. The collaboration aims to leverage Viatris' infrastructure alongside Idorsia's drug development capabilities.
Products Covered:
• Single-dose Auto-Injectors
• Multi-dose Auto-Injectors
Dosages Covered:
• 0.15 mg
• 0.3 mg
• Other Dosages
Age Groups Covered:
• 0-4 Years
• 5-14 Years
• 15-24 Years
• 25-49 Years
• 50-64 Years
• Above 65 Years
• Other Age Groups
Brands Covered:
• EpiPen (Mylan/Viatris)
• Auvi-Q (Kaleo)
• Adrenaclick (Amphastar Pharmaceuticals)
• Generic Versions
• Other Brands
Applications Covered:
• Anaphylaxis
• Food Allergies
• Drug Allergies
• Other Applications
End Users Covered:
• Hospitals
• Clinics
• Homecare Settings
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Epinephrine Auto-Injectors Market, By Product
5.1 Introduction
5.2 Single-dose Auto-Injectors
5.3 Multi-dose Auto-Injectors
6 Global Epinephrine Auto-Injectors Market, By Dosage
6.1 Introduction
6.2 0.15 mg
6.3 0.3 mg
6.4 Other Dosages
7 Global Epinephrine Auto-Injectors Market, By Age Group
7.1 Introduction
7.2 0-4 Years
7.3 5-14 Years
7.4 15-24 Years
7.5 25-49 Years
7.6 50-64 Years
7.7 Above 65 Years
7.8 Other Age Groups
8 Global Epinephrine Auto-Injectors Market, By Brand
8.1 Introduction
8.2 EpiPen (Mylan/Viatris)
8.3 Auvi-Q (Kaleo)
8.4 Adrenaclick (Amphastar Pharmaceuticals)
8.5 Generic Versions
8.6 Other Brands
9 Global Epinephrine Auto-Injectors Market, By Application
9.1 Introduction
9.2 Anaphylaxis
9.3 Food Allergies
9.4 Drug Allergies
9.5 Other Applications
10 Global Epinephrine Auto-Injectors Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Clinics
10.4 Homecare Settings
10.5 Other End Users
11 Global Epinephrine Auto-Injectors Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Viatris Inc.
13.2 Amneal Pharmaceuticals, Inc.
13.3 Teva Pharmaceutical Industries Ltd.
13.4 Kaléo, Inc.
13.5 Pfizer, Inc.
13.6 Sanofi S.A.
13.7 Adamis Pharmaceuticals Corporation
13.8 Novartis International AG
13.9 Bausch Health Companies Inc.
13.10 ALK-Abelló A/S
13.11 Hikma Pharmaceuticals PLC
13.12 Antares Pharma, Inc.
13.13 Meridian Medical Technologies, Inc.
13.14 Becton, Dickinson and Company
13.15 Ypsomed Holding AG
List of Tables
1 Global Epinephrine Auto-Injectors Market Outlook, By Region (2022-2030) ($MN)
2 Global Epinephrine Auto-Injectors Market Outlook, By Product (2022-2030) ($MN)
3 Global Epinephrine Auto-Injectors Market Outlook, By Single-dose Auto-Injectors (2022-2030) ($MN)
4 Global Epinephrine Auto-Injectors Market Outlook, By Multi-dose Auto-Injectors (2022-2030) ($MN)
5 Global Epinephrine Auto-Injectors Market Outlook, By Dosage (2022-2030) ($MN)
6 Global Epinephrine Auto-Injectors Market Outlook, By 0.15 mg (2022-2030) ($MN)
7 Global Epinephrine Auto-Injectors Market Outlook, By 0.3 mg (2022-2030) ($MN)
8 Global Epinephrine Auto-Injectors Market Outlook, By Other Dosages (2022-2030) ($MN)
9 Global Epinephrine Auto-Injectors Market Outlook, By Age Group (2022-2030) ($MN)
10 Global Epinephrine Auto-Injectors Market Outlook, By 0-4 Years (2022-2030) ($MN)
11 Global Epinephrine Auto-Injectors Market Outlook, By 5-14 Years (2022-2030) ($MN)
12 Global Epinephrine Auto-Injectors Market Outlook, By 15-24 Years (2022-2030) ($MN)
13 Global Epinephrine Auto-Injectors Market Outlook, By 25-49 Years (2022-2030) ($MN)
14 Global Epinephrine Auto-Injectors Market Outlook, By 50-64 Years (2022-2030) ($MN)
15 Global Epinephrine Auto-Injectors Market Outlook, By Above 65 Years (2022-2030) ($MN)
16 Global Epinephrine Auto-Injectors Market Outlook, By Other Age Groups (2022-2030) ($MN)
17 Global Epinephrine Auto-Injectors Market Outlook, By Brand (2022-2030) ($MN)
18 Global Epinephrine Auto-Injectors Market Outlook, By EpiPen (Mylan/Viatris) (2022-2030) ($MN)
19 Global Epinephrine Auto-Injectors Market Outlook, By Auvi-Q (Kaleo) (2022-2030) ($MN)
20 Global Epinephrine Auto-Injectors Market Outlook, By Adrenaclick (Amphastar Pharmaceuticals) (2022-2030) ($MN)
21 Global Epinephrine Auto-Injectors Market Outlook, By Generic Versions (2022-2030) ($MN)
22 Global Epinephrine Auto-Injectors Market Outlook, By Other Brands (2022-2030) ($MN)
23 Global Epinephrine Auto-Injectors Market Outlook, By Application (2022-2030) ($MN)
24 Global Epinephrine Auto-Injectors Market Outlook, By Anaphylaxis (2022-2030) ($MN)
25 Global Epinephrine Auto-Injectors Market Outlook, By Food Allergies (2022-2030) ($MN)
26 Global Epinephrine Auto-Injectors Market Outlook, By Drug Allergies (2022-2030) ($MN)
27 Global Epinephrine Auto-Injectors Market Outlook, By Other Applications (2022-2030) ($MN)
28 Global Epinephrine Auto-Injectors Market Outlook, By End User (2022-2030) ($MN)
29 Global Epinephrine Auto-Injectors Market Outlook, By Hospitals (2022-2030) ($MN)
30 Global Epinephrine Auto-Injectors Market Outlook, By Clinics (2022-2030) ($MN)
31 Global Epinephrine Auto-Injectors Market Outlook, By Homecare Settings (2022-2030) ($MN)
32 Global Epinephrine Auto-Injectors Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
